PIM1 and non-small cell lung carcinoma: Based on this remarkable finding, we identify PIM1 as a driver of EMT-associated osimertinib-resistant NSCLC cells and predict that dual EGFR/PIM1 blockade is an effective strategy to prevent and overcome EMT-associated osimertinib resistance.